Published in Obesity and Diabetes Week, December 19th, 2005
The $925,000 increase in revenues for the quarter compared to the prior year period was due to sponsored research and license fee revenue from a collaboration entered into in June 2005 with Merck & Co., Inc. to research, develop and commercialize novel small molecule therapeutics with potential to treat several metabolic diseases, including type 2 diabetes, hyperlipidemia and obesity.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.